JP2015503560A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503560A5
JP2015503560A5 JP2014550335A JP2014550335A JP2015503560A5 JP 2015503560 A5 JP2015503560 A5 JP 2015503560A5 JP 2014550335 A JP2014550335 A JP 2014550335A JP 2014550335 A JP2014550335 A JP 2014550335A JP 2015503560 A5 JP2015503560 A5 JP 2015503560A5
Authority
JP
Japan
Prior art keywords
composition
solid dispersion
hcv
solid
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014550335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503560A (ja
JP5781706B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/070349 external-priority patent/WO2013101550A1/en
Publication of JP2015503560A publication Critical patent/JP2015503560A/ja
Publication of JP2015503560A5 publication Critical patent/JP2015503560A5/ja
Application granted granted Critical
Publication of JP5781706B2 publication Critical patent/JP5781706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014550335A 2011-12-29 2012-12-18 Ｈｃｖ阻害剤を含む固体組成物 Expired - Fee Related JP5781706B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161581146P 2011-12-29 2011-12-29
US61/581,146 2011-12-29
US201261645696P 2012-05-11 2012-05-11
US61/645,696 2012-05-11
PCT/US2012/070349 WO2013101550A1 (en) 2011-12-29 2012-12-18 Solid compositions comprising an hcv inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015140513A Division JP2015227352A (ja) 2011-12-29 2015-07-14 Ｈｃｖ阻害剤を含む固体組成物

Publications (3)

Publication Number Publication Date
JP2015503560A JP2015503560A (ja) 2015-02-02
JP2015503560A5 true JP2015503560A5 (https=) 2015-03-12
JP5781706B2 JP5781706B2 (ja) 2015-09-24

Family

ID=47470243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014550335A Expired - Fee Related JP5781706B2 (ja) 2011-12-29 2012-12-18 Ｈｃｖ阻害剤を含む固体組成物
JP2015140513A Pending JP2015227352A (ja) 2011-12-29 2015-07-14 Ｈｃｖ阻害剤を含む固体組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015140513A Pending JP2015227352A (ja) 2011-12-29 2015-07-14 Ｈｃｖ阻害剤を含む固体組成物

Country Status (9)

Country Link
US (1) US20130172239A1 (https=)
EP (2) EP2797586A1 (https=)
JP (2) JP5781706B2 (https=)
CN (1) CN104010631B (https=)
CA (1) CA2857339C (https=)
DE (1) DE212012000197U1 (https=)
HK (1) HK1201186A1 (https=)
MX (1) MX2014008008A (https=)
WO (1) WO2013101550A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
JP6082749B2 (ja) 2011-11-16 2017-02-15 ギリアド ファーマセット エルエルシー 抗ウイルス化合物としての縮合イミダゾリルイミダゾール
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2846778B1 (en) * 2012-05-07 2018-04-25 Bristol-Myers Squibb Holdings Ireland Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
TW201446286A (zh) * 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
CA2903831A1 (en) * 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of hcv inhibitor in the amorphous state
KR20160005022A (ko) * 2013-03-15 2016-01-13 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 타블렛
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
US20160339074A1 (en) * 2014-02-05 2016-11-24 Merck Sharp & Dohme Corp. Pharmaceutical composition of selective hcv ns3/4a inhibitors
EP3102211A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
KR20160142342A (ko) * 2014-04-03 2016-12-12 산도즈 아게 무정형 소포스부비르를 포함하는 고체 조성물
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016038542A2 (en) * 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
WO2016075588A1 (en) * 2014-11-11 2016-05-19 Sun Pharmaceutical Industries Limited Stable amorphous daclatasvir dihydrochloride
WO2016128453A1 (en) * 2015-02-13 2016-08-18 Sandoz Ag Pharmaceutical compositions comprising ledipasvir and sofosbuvir
WO2016145269A1 (en) 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Solid state forms ledipasvir and processes for preparation of ledipasvir
WO2017021904A1 (en) * 2015-08-03 2017-02-09 Laurus Labs Private Limited Daclatasvir free base and process for the preparation thereof
US20180228826A1 (en) * 2015-08-04 2018-08-16 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017023713A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2017023716A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US20180228827A1 (en) * 2015-08-04 2018-08-16 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20180271890A1 (en) * 2015-10-07 2018-09-27 Sandoz Ag Solid Pharmaceutical Composition Comprising Amorphous Sofosbuvir
WO2017072714A1 (en) 2015-10-30 2017-05-04 Lupin Limited Stable ledipasvir premix and process of preparation thereof
JOP20170127A1 (ar) * 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
RU2019106294A (ru) 2016-08-12 2020-09-21 Сандоз Аг Твердая фармацевтическая композиция, содержащая аморфный софосбувир
WO2018078536A1 (en) 2016-10-26 2018-05-03 Lupin Limited Stable solid dispersion of sofosbuvir and process for preparation thereof
CN106727516A (zh) * 2017-01-10 2017-05-31 山东省立医院 一种治疗丙型肝炎的药物组合物
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
US11378965B2 (en) 2018-11-15 2022-07-05 Toyota Research Institute, Inc. Systems and methods for controlling a vehicle based on determined complexity of contextual environment
CN113209087B (zh) * 2020-02-05 2023-11-07 歌礼药业（浙江）有限公司 一种抑制冠状病毒的药物组合物及其用途
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
KR102842201B1 (ko) * 2023-09-19 2025-08-06 한국해양과학기술원 Lng 추진 선박용 이산화탄소 액화 시스템 및 방법
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
KR20120039763A (ko) * 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008313620A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product containing N-aryl urea-based compound
CA2732777A1 (en) * 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
PL2401272T3 (pl) * 2009-02-27 2017-06-30 Janssen Pharmaceuticals, Inc. Amorficzna sól makrocyklicznego inhibitora HCV
PT3309157T (pt) * 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) * 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
TW201446286A (zh) * 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑

Similar Documents

Publication Publication Date Title
JP2015503560A5 (https=)
CR20120650A (es) Composiciones sólidas
JP2016521119A5 (https=)
HK1201186A1 (en) Solid compositions comprising an hcv inhibitor
JP2013530958A5 (https=)
JP2011105738A5 (https=)
JP2011527299A5 (https=)
JP2015513557A5 (https=)
JP2012144574A5 (https=)
JP2015044981A5 (https=)
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
JP2013542247A5 (https=)
JP2008533007A5 (https=)
JP2013542261A5 (https=)
HK1203514A1 (en) D-amino acid compounds for liver disease
JP2011518833A5 (https=)
CL2007003250A1 (es) Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
JP2014523459A5 (https=)
JP2011518842A5 (https=)
MX368859B (es) Formulaciones de dosis solida de un antagonista del receptor de orexina.
JP2012199532A5 (https=)
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
EP2749582A4 (en) FLUOROUS COPOLYMER AND SURFACE MODIFICATOR THEREFOR AS ACTIVE SUBSTANCE
JP2016530242A5 (https=)
JP2013010936A5 (https=)